Form 8-K Crinetics Pharmaceutical For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Crinetics (CRNX) PT Raised to $56 at Jones Trading
March 19, 2024 1:30 PM EDTJones Trading analyst Catherine Novack raised the price target on Crinetics (NASDAQ: CRNX) to $56.00 (from $52.00) while maintaining a Buy rating.
The analyst comments "Crinetics reported topline Phase 3 PATHFNDR-2 data in acromegaly ( press release ). The data are an unambiguous win, and in... More



